Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1354-1365
Number of pages12
JournalEuropean Journal of Preventive Cardiology
Volume27
Issue number13
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Peripheral arterial disease
  • coronary artery disease
  • rivaroxaban
  • aspirin
  • clopidogrel
  • cost-benefit analysis
  • ARTERY-DISEASE
  • DOUBLE-BLIND
  • REVASCULARIZATION
  • TICAGRELOR
  • GUIDELINES
  • EQ-5D
  • RISK

Cite this